Randomized Phase II Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma

Trial Profile

Randomized Phase II Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs Axitinib (Primary)
  • Indications Adenoid-cystic-carcinoma
  • Focus Therapeutic Use
  • Acronyms AxitinibACC
  • Most Recent Events

    • 05 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 10 Sep 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2017.
    • 13 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top